NASDAQ$WHWK
Whitehawk Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Aadi Bioscience reported financial results for the third quarter of 2021 and provided a business update, highlighting the FYARRO's NDA acceptance and key leadership appointments.
Aadi Bioscience reported a net loss attributable to common stockholders of $87.2 million for the third quarter of 2021, primarily driven by a non-cash impairment charge of $74.2 million. The company ended the quarter with $161.4 million in cash and cash equivalents, which is expected to fund operations into 2024.
- Aadi merged with Aerpio Pharmaceuticals and closed a $155 million PIPE financing.
- The FDA accepted Aadi’s NDA for FYARRO™ with a PDUFA target action date of November 26, 2021.
- Key executive appointments were made, including a Chief Operating Officer.
- A registrational trial in patients harboring TSC1 and TSC2 inactivating alterations is expected to be initiated by the end of 2021 or early 2022.
Headline financials
Revenue & EPS history
Aadi Bioscience · Revenue · Quarterly
$120K
Revenue by segment
Aadi Bioscience · $5.96M total across 1 segment · Q3 2023
- Product Sales, Net$5.96M—100.0%
Forward guidance
Aadi Bioscience anticipates several key developments, including potential regulatory approval and commercial launch of FYARRO, continued clinical trials, and sufficient cash to fund operations into 2024.
Tailwinds
- Potential regulatory approval of FYARRO for advanced malignant PEComa.
- Successful commercialization of FYARRO.
- Advancement of clinical trials for FYARRO in various cancer types.
- Sufficient cash and cash equivalents to fund operations into 2024.
- Planned initiation of a tumor-agnostic registrational trial in mTOR inhibitor-naïve solid tumors.
Headwinds
- Risks related to obtaining regulatory approval from the FDA for FYARRO.
- Uncertainties associated with the clinical development of FYARRO.
- Risk of unforeseen adverse reactions or side effects during FYARRO development.
- Potential failure to realize value from FYARRO.
- Risks related to estimates regarding future expenses and capital requirements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+1.8%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+4.1%
Avg return
30 days after
37%
11 / 30 earnings
Positive
+69.8%
Q1 2021
Best reaction
-18.7%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.3% | -5.5% | -0.7% | |
| Q3 2025 | -0.4% | -3.5% | +10.2% | |
| Q1 2025 | +4.9% | -4.0% | -9.5% | |
| Q4 2024 | -1.5% | +1.2% | +14.7% | |
| Q3 2024 | +5.5% | +5.5% | +21.6% | |
| Q2 2024 | -3.6% | -1.4% | +30.7% | |
| Q1 2024 | -10.9% | -11.4% | -17.5% | |
| Q4 2023 | +5.7% | +9.3% | +1.0% | |
| Q3 2023 | -6.6% | -5.4% | +2.9% | |
| Q2 2023 | -1.0% | +1.7% | -12.2% | |
| Q1 2023 | -18.7% | -17.2% | -4.7% | |
| Q4 2022 | -1.8% | -0.1% | +10.3% | |
| Q3 2022 | +5.1% | +1.2% | +1.7% | |
| Q2 2022 | -6.2% | -0.9% | -11.0% | |
| Q1 2022 | +21.2% | +30.1% | +21.5% | |
| Q4 2021 | +5.4% | +2.3% | -8.2% | |
| Q3 2021 | -16.6% | -8.9% | -13.4% | |
| Q2 2021 | +3.0% | +2.0% | -7.9% | |
| Q1 2021 | +69.8% | +74.1% | +69.0% | |
| Q4 2020 | +1.9% | +2.5% | -15.1% | |
| Q3 2020 | -2.2% | +21.7% | +60.9% | |
| Q2 2020 | +17.3% | +6.4% | -22.4% | |
| Q1 2020 | -0.2% | -1.3% | +82.3% | |
| Q4 2019 | -5.8% | -17.7% | -6.2% | |
| Q3 2019 | -2.6% | -3.6% | +0.9% | |
| Q2 2019 | -1.9% | -1.9% | +0.9% | |
| Q1 2019 | -0.9% | -1.9% | -5.7% | |
| Q4 2018 | +4.2% | +22.4% | -65.0% | |
| Q3 2018 | -1.4% | -11.7% | -2.3% | |
| Q2 2018 | -1.7% | +3.9% | -3.8% | |
| Q4 2011 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro